ArticleHuman vaccines & immunotherapeutics2026
Anti-SARS-CoV-2 response in alveolar blood sample and bronchoalveolar lavage fluid of individuals vaccinated with inactivated COVID-19 vaccines.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal antibody response in lower respiratory tract to COVID-19 vaccines is less studied. This cross-sectional study evaluated the respiratory mucosal antibody response in subjects vaccinated with Aikewei or CoronaVac inactivated COVID-19 vaccines. A total of 39 participants were enrolled June 7 to September 15, 2021, including 16 patients who underwent pneumonectomy and 23 patients who underwent bronchoscopy. IgG to nucleocapsid (N) and spike (S) protein of SARS-CoV-2 (anti-N/S IgG), receptor-binding domain (RBD) of S (anti-RBD IgG), and IgA to N (anti-N IgA) were measured with chemo-luminescence immunoassays. Three patients without vaccination and 10 patients vaccinated with one dose showed negative for these antibodies in peripheral or alveolar blood samples or bronchoalveolar lavage fluid (BALF). Of the 12 patients with pneumonectomy vaccinated with two doses, 11 (91.7%), and 10 (83.3%), and 1 (8.3%) were positive for anti-N/S IgG, anti-RBD IgG, and anti-N IgA in peripheral blood, respectively, whereas the positive rates in alveolar blood samples were 66.7% (8), 66.7% (8), and 0%, respectively, and the median level of anti-N/S and anti-RBD in alveolar blood samples was each significantly lower than that in peripheral blood (10.16 vs. 22.18 AU/ml; 10.24 vs. 15.47 AU/ml, both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.